Translational Pharmaceutics®
Tufts CSDD Study Assessing the Financial Benefits of Translational Pharmaceutics®: A Platform for Accelerating Product Development
This webinar summarizes the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. Access our on-demand webinar now.
Webinar: How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®
Learn about the Translational Pharmaceutics approach and hear insights from our team. Join our webinar in October 2023.
Assessing the Financial Impact of Translational Pharmaceutics®
Seminar: Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics | Doylestown, Pennsylvania
Join us for our upcoming seminar in Doylestown, PA on November 13, entitled "Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics".
Seminar: Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics | Belmont, California
Join us for our upcoming seminar in Belmont, CA on November 9, entitled "Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics".
Seminar: Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics | Del Mar, California
Join us for our upcoming seminar in Del Mar, CA on November 7, entitled "Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics".
Seminar: Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics | South San Francisco, California
Join us for our upcoming seminar in South San Francisco, CA on November 8, entitled "Addressing Complex Oral Formulation Challenges Using Translational Pharmaceutics".
CPHI 2023 Seminar: How To Accelerate Drug Product Optimization: Integrated Program Delivery Using Translational Pharmaceutics®
During CPHI 2023, we will be hosting a seminar entitled, 'How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®'. There are limited spaces available. Register today.
AAPS 2023 Seminar: How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®
During AAPS 2023, we will be hosting a seminar entitled, 'How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®'. There are limited spaces available. Register today.
Assessing the financial impact of Translational Pharmaceutics®
Endevica Case Study - Peptide Program using Translational Pharmaceutics
Endevica Bio is developing TCMCB07 as a novel synthetic peptide product for the potential treatment of cachexia. Read how they leveraged the Quotient Sciences Translational Pharmaceutics platform for this program.
Dramatically Reduce Your Development Time and Costs with Translational Pharmaceutics®
Application of Translational Pharmaceutics® to reduce time, cost and risk in the early development of inhaled drug products - RDD
The efficiency and effectiveness of new drug development has remained problematic over the last decade. Our Translational Pharmaceutics® platform improves R&D productivity.
Application of Translational Pharmaceutics® in Accelerating the Development of MR Dosage Forms
Poster presentation at NERDG 2021 Annual Meeting. In this poster we demonstrate an optimized approach to developing oral modified-release (MR) dosage forms using the Translational Pharmaceutics platform. This approach uses emerging human data to inform adjustment of formulation composition in an adaptive clinical study.
Assessing the Financial Impact of Translational Pharmaceutics®
Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
Accelerating the Development of Enabled Formulations for Poorly Soluble Drugs using Translational Pharmaceutics
This white paper describes the benefits of our approach to poorly soluble drugs in terms of drug product performance and clinical decision-making, including case studies that demonstrate significant time and cost savings.
Translational Pharmaceutics® Fact Sheet
Quotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.
Case Studies: Xspray Pharma
Case Studies: MEI Pharma
AAPS 2019 Poster: A Phase I Study Allowing Clinical Screening of Multiple Solubility-Enhancement Formulation Technologies, and an Assessment of Food, PPI and Dose Linearity Assessment with the Selected Formulation of BOS172767, in Healthy Volunteers
Presented at AAPS 2019: Translational Pharmaceutics was used to evaluate three BOS172767 formulations in on a integrated clinical study, and successfully identified the micronized capsule as the new lead formulation.
Case Studies: BioCryst Pharmaceuticals
Solutions
BioCryst Pharmaceuticals Case Study
BioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.
A rapid formulation development and clinical testing program to evaluate the pharmacokinetics of a novel enabled formulation of abiraterone acetate - AAPS 2016
Following initial dosing, the Translational Pharmaceutics platform also allows GMP drug products to be made in real-time in response to interim analysis of clinical data, typically on a 7-14 day cycle.
Strategies for Achieving Regulatory Milestones Faster
Watch our on-demand webinar featuring a customer case study from Ensysce Biosciences' CEO Lynn Kirkpatrick on choosing an integrated service provider to accelerate drug development.
Strategies for Achieving Regulatory Milestones Faster | Global Webinar
Save your spot for our next webinar featuring a customer case study from Ensysce Biosciences on April 19, 2023. Dr. Vanessa Zann, Senior Drug Development Consultant, will be joined by Lynn Kirkpatrick, CEO of Ensysce Biosciences for this special presentation.
Xspray Pharma Case Study
Protein kinase inhibitors (PKIs) are used in the treatment of cancer and inflammation, but food interactions are a common problem with this class of drugs. Swedish drug delivery company Xspray has used its Hybrid Nanoparticle (HyNap™) technology to improve the bioavailability of the PKI nilotinib, reducing the required dose and significantly lowering the food interaction of the drug compared with the marketed product.
Case Studies: Ensysce Biosciences
AAPS PharmSci 360 2023 | Orlando, FL
Quotient Sciences will be attending and exhibiting at AAPS PharmSci 360 2023 in Orlando from October 22-25.
Pediatrics
First-in-Human to Proof-of-Concept
Our Translational Pharmaceutics approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.
MEI Pharma Case Study
MEI Pharma has leveraged Quotient's Translational Pharmaceutics® platform to expedite development of its next-generation cancer therapy ME-401.
Enhanced formulation decision-making in early phase clinical trials for parenteral products
This presentation describes the principles and applications of Translational Pharmaceutics: an R&D platform integrating formulation development, real-time adaptive GMP manufacturing and clinical testing in order to accelerate drug development cycles.
The Role of Biopharmaceutics in Early Drug Development
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Getting it Right Early: The Importance of Biopharmaceutics in Early Drug Development
Chris Roe, Quotient Sciences' Principal Research Fellow, discusses strategies for overcoming biopharmaceutic challenges for small molecules in today’s drug development.